Antiangiotide

The purpose of this research was to assess the effects of formic acid (FORM) and an herbal mixture (HM) as antibiotic alternatives in broiler meals on growth efficiency, carcass criteria, blood parameters, and intestinal bacterial populations. A total of 360 one-day-old Ross 308 broiler chicks were assigned to six trial treatments using a totally randomized method. Each group consisted of 6 replicates, with 10 unsexed chicks per replicate. The groups were arranged as follows: NC (negative control, basal diet); PC (positive control, basal diet + 0.5 g Polymyxin E antibiotic/kg diet); Form2, Form4, HM3, and HM6 (basal diet supplemented with 2 or 4 ml formic acid, or 3 or 6 g herbal mixture/kg diet, respectively). The findings showed no substantial variations in "body weight (BW) or body weight gain (BWG)" among the formic acid and herbal mixture groups relative to the NC and PC groups. The HM 3 and 6 g/kg groups exhibited higher "feed intake (FI) and improved feed conversion ratio (FCR)" relative to the other treatments. Carcass characteristics were not substantially impacted by formic acid or herbal mixture supplementation, except for spleen weight, which was highest in the NC group. Significant changes in blood parameters were observed, with notable variations in ALT and AST activity and "urea, creatinine, total protein, globulin, and albumin" levels in the formic acid and herbal mixture groups. The supplementation of formic acid and herbal mixture also increased antioxidant levels (GPx, GST, and GSH) compared to the NC group while reducing MDA levels relative to the NC and PC groups. Additionally, formic acid supplementation significantly reduced harmful bacterial populations in cecal samples. Conversely, Lactobacilli counts greater than those in the NC and PC groups, although no significant variances in Clostridium populations were observed. In conclusion, supplementing broiler feed with formic acid and herbal mixtures positively influences blood parameters, antioxidant status, and intestinal microbiota.

Contemporary durable left ventricular assist devices (LVAD) have established current benchmarks for patient outcomes, but introduction of more novel technology is lacking. The BrioVAD System (BrioHealth Solutions, Burlington, MA) is an innovative, fully magnetically levitated pump intended to provide short-term (ST) and long-term (LT) mechanical circulatory support.

The Investigation of a Novel, MagNetically Levitated VAD for the Treatment of RefractOry Left Ventricular HeArT FailurE Clinical Trial (INNOVATE) is designed to evaluate safety and efficacy of the BrioVAD by demonstrating non-inferiority to the HeartMate 3 (HM3; Abbott Labs, Chicago, IL). INNOVATE is a multi-center, prospective, non-blinded, randomized (2 BrioVAD: 1 HM3), controlled, non-inferiority study designed as a staged pivotal study with a pre-defined safety phase. Exclusion criteria are designed to enroll a patient population that aligns with contemporary clinical practice. Primary endpoints include a composite of survival to transplant, cardiac recovery, or 6 months (ST) or 24 months (LT) of LVAD support free from debilitating stroke (modified Rankin Scale > 3), or reoperation to replace the pump. A powered secondary outcome evaluates days spent in hospital, skilled nursing facility, or inpatient rehabilitation.

INNOVATE study screening and enrollment began in 2024. Completed enrollment of the safety cohort (n = 45) is projected in early 2025. Completion of the ST cohort (n = 237) and LT cohort (n = 402) is projected for 2026 and 2027, respectively.

INNOVATE represents a contemporary clinical trial design evaluating unique design features of the BrioVAD System with the expectation to improve patient outcomes.